# TG Therapeutics (stock symbol: TGTX) Logo in transparent PNG and SVG formats

## TG Therapeutics Logo large

### TG Therapeutics Logo large Download PNG (21.99 KB)

![TG Therapeutics Logo large Download PNG (21.99 KB)](/img/orig/TGTX_BIG-fbca9825.png)

### TG Therapeutics Logo large Download SVG (4.3 KB)

![TG Therapeutics Logo large Download SVG (4.3 KB)](/img/orig/TGTX_BIG-49645ae3.svg)

## TG Therapeutics Logo icon format

### TG Therapeutics Logo icon format Download PNG (18.36 KB)

![TG Therapeutics Logo icon format Download PNG (18.36 KB)](/img/orig/TGTX-be3cd404.png)

### TG Therapeutics Logo icon format Download SVG (776 Bytes)

![TG Therapeutics Logo icon format Download SVG (776 Bytes)](/img/orig/TGTX-8334cb8d.svg)

## TG Therapeutics Logo large for dark backgrounds

### TG Therapeutics Logo large for dark backgrounds Download PNG (13.97 KB)

![TG Therapeutics Logo large for dark backgrounds Download PNG (13.97 KB)](/img/orig/TGTX_BIG.D-6415a11c.png)

### TG Therapeutics Logo large for dark backgrounds Download SVG (4.22 KB)

![TG Therapeutics Logo large for dark backgrounds Download SVG (4.22 KB)](/img/orig/TGTX_BIG.D-d7930d62.svg)

## TG Therapeutics Logo icon format for dark backgrounds

### TG Therapeutics Logo icon format for dark backgrounds Download PNG (18.36 KB)

![TG Therapeutics Logo icon format for dark backgrounds Download PNG (18.36 KB)](/img/orig/TGTX.D-51025d9e.png)

### TG Therapeutics Logo icon format for dark backgrounds Download SVG (776 Bytes)

![TG Therapeutics Logo icon format for dark backgrounds Download SVG (776 Bytes)](/img/orig/TGTX.D-eb6b8f62.svg)

## About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

1. Website domain: tgtherapeutics.com
2. Employees: 186
3. Marketcap: $3.63 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
